Goldman Sachs Puts MeiraGTx on Watch with Neutral Rating

Goldman Sachs has initiated coverage of MeiraGTx Holdings plc (MGTX) with a neutral rating and a price target of $16.00, representing upside potential from the current stock price of $11.75.

The company's lead asset, bota-vec, targets X-linked retinitis pigmentosa, while its Lilly-partnered AAV-AIPL1 addresses LCA4 congenital blindness.

MeiraGTx plans to initiate a Phase 3 AAV-GAD trial for Parkinson’s disease via joint venture Reogen and has secured a substantial investment agreement with Oberland Capital Management potentially amounting to $400 million.